RASH
MCID: EXN002
MIFTS: 58

Exanthem (RASH)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Exanthem

MalaCards integrated aliases for Exanthem:

Name: Exanthem 12 15 17
Exanthema 12 44
Rash 12 15
Rashes 43

Classifications:



External Ids:

Disease Ontology 12 DOID:0050486
ICD9CM 35 782.1
MeSH 44 D005076
SNOMED-CT 68 1806006
ICD10 33 R21
UMLS 72 C0015230

Summaries for Exanthem

MedlinePlus : 43 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to drug reaction with eosinophilia and systemic symptoms and meningitis. An important gene associated with Exanthem is CD40LG (CD40 Ligand), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Morphine and Vancomycin have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

Wikipedia : 75 An exanthem is a widespread rash usually occurring in children. An exanthem can be caused by toxins,... more...

Related Diseases for Exanthem

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 415)
# Related Disease Score Top Affiliating Genes
1 drug reaction with eosinophilia and systemic symptoms 30.9 TNF CRP
2 meningitis 30.9 TNF NLRP3 CRP
3 aseptic meningitis 30.7 TNF NLRP3 IL1RN
4 exanthema subitum 30.6 TNFRSF1B IL2 CD40LG
5 schnitzler syndrome 30.5 NLRP3 IL1RN CRP
6 pustulosis of palm and sole 30.4 TNFRSF1B TNF IL1RN
7 vasculitis 30.3 TNFRSF1B TNF CRP CD40LG
8 adult-onset still's disease 30.3 TNF IL1RN CRP
9 lyme disease 30.2 TNF CRP CD40LG
10 pericarditis 30.1 TNF IL1RN CRP
11 arthropathy 30.0 TNF NLRP3 CRP
12 synovitis 29.9 TNF IL1RN CRP
13 systemic scleroderma 29.9 TRIM21 CRP CD40LG
14 familial mediterranean fever 29.9 TNF NLRP3 IL1RN CRP
15 spondyloarthropathy 1 29.8 TNFRSF1B TNF CRP
16 pustulosis palmaris et plantaris 29.8 TNF CD40LG CCR6
17 spondylitis 29.7 TNFRSF1B TNF IL1RN CRP
18 juvenile rheumatoid arthritis 29.7 TNFRSF1B TNF IL1RN CRP
19 paronychia 29.6 MTOR KRAS HRAS EGFR
20 acquired immunodeficiency syndrome 29.2 TNF IL2 CD4
21 viral infectious disease 29.0 TNF IL2 GPT CD40LG CD4
22 brucellosis 28.9 TNF IL2 IL1RN CRP CD40LG
23 thymoma 28.8 MTOR IL2 HRAS EGFR
24 myeloma, multiple 28.7 TNF KRAS IL2 HRAS CRP
25 sarcoidosis 1 28.3 TNFRSF1B TNF IL2
26 rheumatoid arthritis 28.3 TNFRSF1B TNF IL2 IL1RN CRP CD40LG
27 leukemia, acute myeloid 27.9 TNF MTOR KRAS IL2 HRAS
28 systemic lupus erythematosus 27.9 TRIM21 TNFRSF1B TNF IL2 CRP CD40LG
29 bacterial exanthem 12.5
30 viral exanthem 12.5
31 hand, foot and mouth disease 11.8
32 pityriasis rosea 11.6
33 wissler's syndrome 11.3
34 contagious pustular dermatitis 11.2
35 breast intraductal proliferative lesion 10.7 ERBB2 EGFR
36 sigmoid neoplasm 10.6 KRAS HRAS
37 cryopyrin-associated periodic syndrome 10.6 NLRP3 IL1RN CRP
38 apocrine adenoma 10.5 KRAS HRAS
39 measles 10.5
40 ventilation pneumonitis 10.5 TNF CD4
41 chickenpox 10.5
42 lung benign neoplasm 10.5 KRAS HRAS EGFR
43 pyomyositis 10.5 GPT CRP
44 pericardium disease 10.4 TRIM21 IL1RN CRP
45 colonic disease 10.4 KRAS HRAS EGFR
46 colorectal adenocarcinoma 10.4 KRAS HRAS EGFR
47 breast scirrhous carcinoma 10.4 ERBB2 EGFR
48 pneumocystosis 10.4 TNF CD40LG CD4
49 ovary adenocarcinoma 10.4 KRAS HRAS ERBB2
50 vulvar vestibulitis syndrome 10.4 TNF NLRP3 IL1RN

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem

Symptoms & Phenotypes for Exanthem

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 EGFR HRAS KRAS MTOR
2 Decreased viability GR00106-A-0 10.3 KRAS
3 Decreased viability GR00221-A-1 10.3 EGFR HRAS KRAS MTOR
4 Decreased viability GR00221-A-2 10.3 HRAS KRAS
5 Decreased viability GR00221-A-3 10.3 HRAS
6 Decreased viability GR00221-A-4 10.3 EGFR MTOR
7 Decreased viability GR00301-A 10.3 KRAS
8 Decreased viability GR00342-S-1 10.3 MTOR
9 Decreased viability GR00342-S-2 10.3 MTOR
10 Decreased viability GR00381-A-1 10.3 KRAS
11 Decreased viability GR00402-S-2 10.3 EGFR HRAS KRAS MTOR
12 Decreased viability with paclitaxel GR00179-A-1 9.9 EGFR MTOR ERBB2
13 Decreased viability with paclitaxel GR00179-A-2 9.9 MTOR
14 Decreased viability with paclitaxel GR00179-A-3 9.9 EGFR MTOR
15 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.72 EGFR ERBB2 HRAS HSPG2 MTOR
16 Increased cell migration GR00055-A-3 9.26 EGFR HRAS KRAS MTOR
17 Reduced mammosphere formation GR00396-S 9.17 CCR6 EGFR HRAS HSPG2 KRAS MTOR

MGI Mouse Phenotypes related to Exanthem:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 CCR6 CD4 CD40LG CRP EGFR ERBB2
2 cellular MP:0005384 10.39 CD4 CD40LG CD8A EGFR ERBB2 HSPG2
3 hematopoietic system MP:0005397 10.37 CCR6 CD4 CD40LG CD8A EGFR HSPG2
4 immune system MP:0005387 10.37 CCR6 CD4 CD40LG CD8A CRP EGFR
5 cardiovascular system MP:0005385 10.36 CD40LG CRP EGFR ERBB2 HRAS HSPG2
6 mortality/aging MP:0010768 10.34 CD4 CD40LG CD8A CDAN1 EGFR ERBB2
7 growth/size/body region MP:0005378 10.31 CD4 EGFR ERBB2 HRAS HSPG2 IL1RN
8 endocrine/exocrine gland MP:0005379 10.29 CD4 CD40LG CD8A EGFR ERBB2 HRAS
9 integument MP:0010771 10.29 CD4 CD40LG CD8A EGFR ERBB2 HRAS
10 digestive/alimentary MP:0005381 10.26 CD4 EGFR ERBB2 HRAS HSPG2 IL2
11 nervous system MP:0003631 10.18 CCR6 CD4 CD40LG CD8A EGFR ERBB2
12 craniofacial MP:0005382 10.11 EGFR ERBB2 HRAS HSPG2 KRAS TNF
13 liver/biliary system MP:0005370 10 EGFR HSPG2 IL2 KRAS NLRP3 TNF
14 normal MP:0002873 10 CCR6 CD4 CD8A CDAN1 EGFR ERBB2
15 neoplasm MP:0002006 9.95 EGFR ERBB2 HRAS IL2 KRAS TNF
16 no phenotypic analysis MP:0003012 9.87 CD4 EGFR HRAS IL2 KRAS MTOR
17 renal/urinary system MP:0005367 9.81 CD40LG CD8A EGFR HRAS KRAS MTOR
18 respiratory system MP:0005388 9.61 EGFR ERBB2 HRAS HSPG2 IL2 KRAS
19 skeleton MP:0005390 9.4 CD40LG EGFR ERBB2 GPT HRAS HSPG2

Drugs & Therapeutics for Exanthem

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 718)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4 57-27-2 5288826
2
Vancomycin Approved Phase 4 1404-90-6 441141 14969
3
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
4
Enalaprilat Approved Phase 4 76420-72-9 6917719
5
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
6
Cefazolin Approved Phase 4 25953-19-9 656510 33255
7
Nevirapine Approved Phase 4 129618-40-2 4463
8
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
9
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
10
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
11
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
12
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
13
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
14
Cefpirome Approved Phase 4 84957-29-9 5479539
15
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
16
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
19
Polyestradiol phosphate Approved Phase 4 28014-46-2
20
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
21
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
22
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
23
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
24
Methyltestosterone Approved Phase 4 58-18-4 6010
25
Testosterone enanthate Approved Phase 4 315-37-7 9416
26
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
27
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
28
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
29
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
30
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
31
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
32
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
33
Ledipasvir Approved Phase 4 1256388-51-8 67505836
34
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
35
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
36
Azithromycin Approved Phase 4 83905-01-5 447043 55185
37
Topiramate Approved Phase 4 97240-79-4 5284627
38
Sulfamethoxazole Approved Phase 4 723-46-6 5329
39
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
40
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
41
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
42
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
43
Amantadine Approved Phase 4 768-94-5 2130
44
Nicotine Approved Phase 4 54-11-5 942 89594
45
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
46
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
47
Fenofibrate Approved Phase 4 49562-28-9 3339
48
Clarithromycin Approved Phase 4 81103-11-9 84029
49
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
50
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606

Interventional clinical trials:

(show top 50) (show all 727)
# Name Status NCT ID Phase Drugs
1 Non-randomized Phase-IV-study to Investigate the Efficacy of FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
2 Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
3 Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy Unknown status NCT02383797 Phase 4
4 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
5 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
6 Evaluation Whether Higher Retention Rate is in Those of Combined Methadone With N-Acetyl-Cysteine Compared to Those With Methadone Alone During a Six-month Study Unknown status NCT01047956 Phase 4 Methadone; NAC;Methadone
7 A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement Unknown status NCT01069042 Phase 4 Enalapril
8 An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
9 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods for Supratentorial Craniotomy by Integrated Pulmonary Index (IPI) Unknown status NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
10 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
11 IDC 56: A Randomized Double-blinded Study Comparing Ceftaroline to Standard of Care Therapy With Cefazolin and Vancomycin as Surgical Prophylaxis for High Risk Orthopedic and Cardiac Surgeries Unknown status NCT02307006 Phase 4 Ceftaroline;Cefazolin / Vancomycin
12 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
13 A Parallel, Evaluator-Blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Two Marketed Topical Skin Protectants Containing Zinc Oxide in Children With Diaper Rash Completed NCT00219466 Phase 4
14 A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster Completed NCT02152800 Phase 4 valacyclovir hydrocholoride
15 A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. Completed NCT02184299 Phase 4 Nevirapine;Prednisone
16 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed NCT02958345 Phase 4
17 Prospective 2-Year Longitudinal Study to Assess for Miconazole Resistance in Candida Spp. With Repeated Treatment Courses of 0.25% Miconazole Nitrate Ointment in Neonates and Infants up to 1 Year of Age With Recurrent Moderate-Severe Diaper Dermatitis Complicated by Cutaneous Candidiasis Completed NCT00702507 Phase 4 0.25 % Miconazole Nitrate Ointment
18 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
19 Physiologic Testosterone Replacement in Women With Hypopituitarism Completed NCT00144391 Phase 4 Transdermal Testosterone gel
20 Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia Completed NCT00885586 Phase 4 gabapentine
21 Aloe Vera and Chlorhexidine as Preventive Oral Antiseptics Against the Appearance of Traumatic Oral Ulcers in Patients With Fixed Orthodontics: a Randomized Clinical Trial Completed NCT03633292 Phase 4 Antiseptic clorhexidine gel (Lacer, Barcelona, Spain);Master formula of aloe vera gel 80%
22 A Multi-center, Double-blinded Randomized Trial for Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
23 Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome Completed NCT02961998 Phase 4 Celecoxib;Sorafenib
24 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS) Completed NCT00200941 Phase 4 Topiramate
25 Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial. Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
26 The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment Completed NCT01318356 Phase 4 Doxycycline;Placebo
27 A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain: A Randomized Control Trial Completed NCT03221946 Phase 4 Diclofenac Sodium;Diclofenac sodium;Diclofenac
28 Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy Completed NCT00617643 Phase 4 Nevirapine without dose escalation;Nevirapine initiation with dose escalation
29 A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients Completed NCT00127972 Phase 4 stavudine;lamivudine;nevirapine;efavirenz;trizivir
30 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
31 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
32 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
33 The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs. Completed NCT02347345 Phase 4 Harvoni (Fixed dose combination ledipasvir/sofosbuvir)
34 Proteomic Profiling for Influenza Vaccination Completed NCT00133588 Phase 4
35 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
36 A Comparison of Bupropion SR and Placebo for Smoking Cessation Completed NCT00176449 Phase 4 Bupropion SR;Placebo Oral Tablet
37 A Double Blinded Randomized Controlled Trial to Compare the Efficacy, Time to Onset, and Duration of Two Botulinum Type A Exotoxins (Onabotulinum Toxin A and Abobotulinum Toxin A) in the Treatment of "Crow's Feet." Completed NCT01529788 Phase 4 Right lateral orbital injection of Botox Cosmetic or Dysport;Left lateral orbital injection of Botox Cosmetic or Dysport
38 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
39 Efficacy and Safety of Extended Release Niacin-Fenofibrate Combination and Monotherapy for the Treatment of Atherogenic Dyslipidemia in Obese Females Completed NCT03615534 Phase 4 Fenofibrate
40 A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation Completed NCT01192724 Phase 4 Cilostazol;Aspirin;Clopidogrel
41 A Pilot Evaluation of the Pharmacokinetics, Efficacy and Safety of Switching From Efavirenz to Maraviroc Administered at 600mg Then 300mg Twice-daily in Patients Suppressed on an Efavirenz-containing Regimen as Initial Therapy Completed NCT01190293 Phase 4 Maraviroc
42 A Prospective, Randomized, Double Blind Study Comparing the Efficacy and Safety of Fentanyl Nasal Spray to Placebo as an Analgesic, in Patients Undergoing Outpatient Cystoscopic Procedures Completed NCT01708122 Phase 4 Fentanyl;saline
43 Comparative Study of the Levofloxacin-Based and Clarithromycin-Based Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication and Change of Gut Flora and Drug Susceptibility Before and After Treatment Completed NCT00816140 Phase 4 Cravit based triple therapy;Klaricid based triple therapy
44 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
45 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
46 Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication Completed NCT03650543 Phase 4 amoxicillin clarithromycin omeprazole 1;amoxicillin clarithromycin omeprazole 2
47 Pneumonia in Children: Aetiology, Ideal Antibiotic Duration, Quality of Life Completed NCT02258763 Phase 4 Amoxicillin-Potassium Clavulanate Combination;Placebo
48 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
49 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial Completed NCT03052998 Phase 4 Ivermectin
50 EFFICACY OF KETAMINE-PROPOFOL COMBINATION FOR SHORT SURGICAL PROCEDURES Completed NCT01651988 Phase 4 Ketamina-Propofol Combination

Search NIH Clinical Center for Exanthem

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Camphor
Diphenhydramine
Palmitic Acid

Cochrane evidence based reviews: exanthema

Genetic Tests for Exanthem

Anatomical Context for Exanthem

MalaCards organs/tissues related to Exanthem:

41
Skin, Lung, Breast, Testes, Liver, T Cells, Bone

Publications for Exanthem

Articles related to Exanthem:

(show top 50) (show all 25217)
# Title Authors PMID Year
1
Association of atopic dermatitis with obesity via a multi-omics approach: A protocol for a case-control study. 17
31335732 2019
2
Characteristics of meibomian gland dysfunction in patients with Stevens-Johnson syndrome. 17
31261544 2019
3
Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology. 17
31166406 2019
4
Allergic myocardial infarction: Type I Kounis syndrome following blue crab consumption. 38
30325266 2019
5
Ramsay Hunt syndrome: a rare complication of herpes zoster infection in a lung cancer patient. 38
30189789 2019
6
Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study. 38
31010330 2019
7
Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. 38
30086678 2019
8
Osteoarticular manifestations of Mayaro virus infection. 38
31361271 2019
9
[Idiopathic granulomatous mastitis associated with erythema nodosum]. 38
31151772 2019
10
[Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies]. 38
30929872 2019
11
Mittens and Booties Syndrome: A Unique Manifestation of Human Parechovirus Infection in Infants. 38
31408057 2019
12
Newborn ear defomities and their treatment efficiency with Earwell infant ear correction system in China. 38
31195304 2019
13
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. 38
31090044 2019
14
A 10-year-old boy with fever, arthritis, and a painful rash. 38
31379426 2019
15
Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Probably Related to Cefpodoxime: A Case Report. 38
31382812 2019
16
A rare and severe cutaneous adverse effect of telaprevir: drug rash with eosinophilia and systemic symptoms. 38
31251007 2019
17
Rash developing after cessation of Daclizumab for relapsing remitting MS; a case series. 38
31421627 2019
18
Drug rash versus Immune reconstitution inflammatory syndrome (IRIS)- a diagnostic dilemma. 38
31400204 2019
19
Incomplete Stevens-Johnson Syndrome Caused by Sulfonamide Antimicrobial Exposure. 38
31404173 2019
20
Non-ST-Elevation Myocardial Infarction-Like Syndrome in Scombroid Tuna Fish Poisoning. 38
31221463 2019
21
Superficial and Deep Cutaneous Involvement by RAS-Associated Autoimmunne Leukoproliferative Disease (RALD Cutis): A Histologic Mimicker of Histiocytoid Sweet Syndrome. 38
31335417 2019
22
TNF-α blockers for the treatment of Kawasaki disease in children. 38
31425625 2019
23
Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. 38
30706337 2019
24
Necrotising fasciitis complicating hand, foot and mouth disease. 38
31434667 2019
25
An unusual cutaneous manifestation of Parvovirus B19 infection: papular-purpuric gloves-and-socks syndrome and petechial bathing trunk eruption. 38
31400151 2019
26
Increased Type 2 Innate Lymphoid Cells in Patients with Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome. 38
30735685 2019
27
Case Report: Cardiac Tamponade in Dengue Hemorrhagic Fever: An Unusual Manifestation of a Common Disease. 38
31162011 2019
28
New and old hotspots for rickettsial spotted fever acquired in Tasmania, 2012-2017. 38
31268225 2019
29
Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre. 38
31050373 2019
30
A practical 16-day Desensitization Protocol in Lenalidomide induced Non-immediate Hypersensitivity Reactions. 38
31400463 2019
31
Drug reaction with eosinophilia and systemic symptoms: Pediatric case series and literature review. 38
31423638 2019
32
Generalized Cytokine Increase in the Setting of a Multisystem Clinical Disorder and Carcinoid Syndrome Associated with a Novel NLRP12 Variant. 38
30788684 2019
33
Pain, swelling and irritability in the sun: what is the diagnosis? 38
31434640 2019
34
Outbreak of human monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. 38
31285143 2019
35
Case series of an alternative therapy for generalised lichen planus: Four case studies. 38
31384327 2019
36
Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article. 38
31393368 2019
37
A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. 38
31397829 2019
38
Evaluation of the trends in the incidence of infectious diseases using the syndromic surveillance system, early warning and response unit, Mongolia, from 2009 to 2017: a retrospective descriptive multi-year analytical study. 38
31399064 2019
39
A rare case of purpuric rash caused by Saprochaete clavata in a pediatric patient with acute leukemia. 38
31423625 2019
40
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. 38
31400961 2019
41
Atypical cutaneous targetoid lesions after bone marrow transplant. 38
31409617 2019
42
Oligodendrocyte Kir4.1 Channels Clear Out Congested K. 38
31409147 2019
43
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report. 38
31374006 2019
44
Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score. 38
31199595 2019
45
Adverse cutaneous effects of neratinib. 38
30321080 2019
46
Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. 38
30953238 2019
47
Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. 38
30987435 2019
48
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. 38
31180194 2019
49
Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. 38
31413534 2019
50
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. 38
31305287 2019

Variations for Exanthem

Expression for Exanthem

Search GEO for disease gene expression data for Exanthem.

Pathways for Exanthem

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 87)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TNFRSF1B TNF MTOR KRAS IL2 HSPG2
2
Show member pathways
13.66 TNFRSF1B TNF MTOR KRAS IL2 IL1RN
3
Show member pathways
13.65 TRIM21 TNFRSF1B TNF NLRP3 MTOR KRAS
4
Show member pathways
13.6 TNFRSF1B TNF MTOR KRAS IL2 HRAS
5
Show member pathways
13.48 TRIM21 MTOR KRAS HRAS ERBB2 EGFR
6
Show member pathways
13.27 TNF MTOR KRAS IL2 HRAS ERBB2
7
Show member pathways
13.26 TNFRSF1B TNF MTOR KRAS IL2 HRAS
8
Show member pathways
13.22 TNFRSF1B TNF KRAS IL2 HRAS ERBB2
9
Show member pathways
13.12 MTOR KRAS IL2 HSPG2 HRAS EGFR
10
Show member pathways
13.11 TRIM21 TNFRSF1B TNF KRAS IL2 IL1RN
11
Show member pathways
13.03 TNF MTOR KRAS IL2 HRAS ERBB2
12
Show member pathways
12.99 TNFRSF1B TNF MTOR KRAS HRAS EGFR
13
Show member pathways
12.98 TNFRSF1B TNF KRAS HRAS EGFR CD40LG
14
Show member pathways
12.97 TNFRSF1B TNF MTOR KRAS HSPG2 HRAS
15
Show member pathways
12.91 TNFRSF1B TNF IL2 HRAS CD8A CD40LG
16 12.9 MTOR KRAS IL2 HRAS ERBB2 EGFR
17 12.82 TNF KRAS HRAS ERBB2 EGFR
18
Show member pathways
12.82